bidity and mortality in immunologically vulnerable groups such as transplant recipients, AIDS patients, and pregnant women with their developing fetuses (4, 5) . Congenital HCMV infection is a leading cause of fetal abnormalities, which most commonly results in microcephaly, intellectual impairment, sensorineural hearing loss, and, in rare cases, even death and multiorgan failure (2, 6) . Permanent birth defects are associated more frequently with congenital HCMV infection than with other well-known childhood diseases, including trisomy 21, spina bifida, or fetal alcohol syndrome (2, 5, (7) (8) (9) . Given the medical, societal, and economical benefits for the human population that would result from an effective HCMV vaccine, the Institute of Medicine assessed HCMV vaccine development as a major public health priority. Despite this assessment and research efforts that span more than 4 decades, a vaccine candidate that effectively prevents HCMV infection remains elusive.
Although the immune responses that correlate with protection against HCMV infection are only poorly defined, the induction of neutralizing antibodies (NAb) that block virus entry into host cells is thought to contribute to the prevention of HCMV infection (10) (11) (12) (13) (14) (15) . Most subunit vaccine strategies have focused on envelope glycoprotein B (gB) as an immunogen based on its essential role in HCMV entry, abundance in the virion envelope, and immunodominance in eliciting fibroblast (FB)-specific NAb in HCMV-seropositive (HCMV ϩ ) individuals (16, 17) . These efforts culminated in the clinical findings obtained with gB admixed in the adjuvant MF59, showing efficacy rates of 50% and 43% in preventing primary infection in HCMV-seronegative (HCMV Ϫ ) women and adolescent girls, respectively and an ability to significantly reduce viremia in transplant patients (18) (19) (20) . These encouraging results with gB/MF59 indicate that other antigen compositions or vaccine formulations with an improved ability to stimulate humoral or cellular immune responses could confer levels of protection against HCMV that are considered sufficient for having a significant health impact (21) .
Many findings obtained over the past years suggest that NAb targeting the HCMV envelope pentamer complex (PC) composed of gH, gL, UL128, UL130, and UL131A play a critical role in preventing congenital HCMV infection (12, 13) . While the glycoprotein complexes gB and gH/gL/gO appear necessary for HCMV entry into all susceptible cell types, the PC is dispensable for HCMV entry into FBs but is required for virus entry into many other important cell types, such as epithelial cells (EC), endothelial cells, monocytes/macrophages, and dendritic cells (22) (23) (24) (25) (26) (27) . Most importantly from the vaccine point of view, NAb that block PC-mediated steps of HCMV entry are substantially more potent than are NAb that interfere with the entry function of gB or gH/gL/gO (28) (29) (30) (31) .
In addition, we recently demonstrated that PC-specific antibodies have a potent ability to neutralize infection of primary cytotrophoblasts, which are considered the key placental cells that HCMV utilizes to cross the fetal-maternal interface (32) . In line with these in vitro data, there is evidence for a correlation of NAb to the PC and reduced virus spread in vivo as well as a reduced risk of intrauterine virus transmission (12, 13) . As a consequence of these observations, many innovative vaccine strategies based on the PC have been preclinically evaluated, which consistently showed that the PC is a potent immunogen to elicit NAb that block HCMV entry into EC and other cells (29, 30, 33, 34) . Collectively, these results suggest that the stimulation of PC-specific NAb could be an important immune component for a vaccine candidate to prevent or control congenital HCMV infection.
However, the epitope sequences that are recognized by PC-specific NAb are only poorly defined. Here, we describe a continuous binding site within UL128 that is recognized by a potent NAb previously raised in mice by a modified vaccinia virus Ankara (MVA) vector coexpressing all five PC subunits (30, 32) . The identified 13B5 target site comprises at minimum a 13-amino-acid-long sequence at the C terminus of UL128 and has a similar affinity for binding of the 13B5 antibody compared to that of the purified PC. In addition, this binding site is universally conserved in HCMV and localized at a previously described putative critical interaction site of UL128 and gL (35) . Furthermore, peptides based on this target sequence have the ability to interfere with HCMV neutralization and to elicit HCMV-specific NAb in mice. These observations indicate the discovery of a continuous neutralizing epitope within the UL128 subunit of the PC that could be an important target of potentially protective HCMV-specific humoral immune responses.
RESULTS
NAb 13B5 binds a linear sequence within UL128. We recently isolated a panel of NAb from MVA-PC-immunized mice that showed antigen recognition and neutralization potency that were similar to those of human PC-specific NAb previously isolated from HCMV ϩ individuals (32) . Intracellular flow cytometry staining of the PC subunits expressed either alone or in different combinations with one another revealed that most of the isolated NAb recognized conformational epitopes requiring the assembly of two or more PC subunits (UL130/UL131A or UL128/UL130/UL131A). However, similarly to NAb isolated from HCMV ϩ individuals, one potent NAb, termed 13B5, that we isolated showed binding to UL128 when expressed individually or in any combination with the other PC subunits, but it did not show binding in the absence of UL128, indicating that it recognizes an epitope constituted by UL128 alone (32) . To determine whether NAb 13B5 recognizes a continuous or discontinuous sequence within UL128, we performed Western blot analysis with the 13B5 antibody to detect UL128 under denaturing and reducing conditions following its expression as a single subunit or together with all other PC subunits from adenovirus (Ad) vectors in ARPE-19 EC. For comparison, we used identical concentrations of a well-characterized anti-UL128 antibody, termed Z9G11, that lacks neutralization activity and that we routinely use to confirm UL128 expression from our MVA constructs (31) . As shown in Fig. 1 , antibodies 13B5 and Z9G11 demonstrated similar antigen recognition of UL128 under denaturing/ reducing conditions via Western blotting. Slightly lower recognition signals were observed with 13B5 than with Z9G11. These results suggest that the potent NAb 13B5 that was isolated from MVA-PC-immunized mice targets a continuous binding site within UL128, and this interaction presumably does not require disulfide bonding between UL128 and gL.
NAb 13B5 targets a binding site that is localized at the UL128 C terminus. Based on data from the Western blot analyses that suggested 13B5 recognition of a continuous sequence within UL128, we proceeded to precisely map the 13B5 binding site using peptide-based scanning methods. Therefore, we synthesized a UL128 peptide library consisting of 15-mers with an offset of 4 for a total of 41 peptides (Table 1) and evaluated 13B5 binding to the synthesized peptides via an enzyme-linked immunosorbent assay (ELISA). For comparison, we determined the binding of the UL128-specific nonneutralizing Ab Z9G11. As shown in Fig. 2 , NAb 13B5 reacted with three peptides, peptides 39, 40, and 41, that span the extreme C-terminal part of UL128. The strongest binding was observed with peptide 40, which was composed of the sequence 157-K RLDVCRAKMGYMLQ-171, indicating that this peptide contains the major amino acid residues that are required for 13B5 binding. Note that 13B5 did not show reactivity with any other peptides besides peptides 39, 40, and 41, supporting that only the C-terminal part of UL128 contains amino acid sequences that constitute the 13B5 target site. In contrast to NAb 13B5, nonneutralizing Ab Z9G11 demonstrated strong binding to three peptides at the UL128 N terminus: peptides 7, 8, and 9. Notably, not all peptides bind to plastic with the same efficiency. Hence, the ELISA data presented in Fig. 2 (and Fig.  3 ) may be biased by certain peptides failing to bind efficiently to the ELISA plate wells considering that the UL128 library peptides vary significantly. Nonetheless, these results indicated that the target epitope of NAb 13B5 is located at the C terminus of UL128, while the target site of nonneutralizing Ab Z9G11 is located at the N terminus of the protein.
The UL128 binding site of NAb 13B5 is only minimally reactive with antibodies from HCMV ؉ individuals. Since NAb 13B5 was isolated from mice immunized with MVA-PC, we investigated whether HCMV ϩ individuals develop antibodies to the UL128 binding site of NAb 13B5 following natural HCMV infection. To address this, commercially available antisera from three HCMV ϩ individuals and CMV hyperimmune globulins that represent an antibody pool of over 1,000 HCMV ϩ individuals (36) were evaluated by an ELISA to assess whether the human antisera contained antibodies that bound to the peptides of the UL128 peptide library. We identified two regions in UL128 that showed strong binding of human antibodies, corresponding to peptides 6 to 9 at the N terminus and peptides 37 to 39 at the C terminus of the UL128 amino acid sequence (Fig. 3) . Interestingly, C-terminal peptide 40 of UL128 containing the 13B5 binding site reacted only minimally with human antibodies, while peptides comprising the target site of nonneutralizing Ab Z9G11 (peptides 7, 8, and 9) showed very strong binding with the antibody preparations (Fig. 3) . Hence, these data may suggest that the 13B5 target site within UL128 is not a dominant HCMV PC epitope sequence, or it is only poorly recognized by antibodies induced by HCMV during natural infection. In contrast, the UL128 target site of nonneutralizing Ab Z9G11 appears to be located at a region that is highly reactive with antibodies found in HCMV-infected individuals. The UL128 binding site of NAb 13B5 is universally conserved in HCMV. UL128, UL130, and UL131A are known to be highly conserved in HCMV and hence are considered excellent targets for the development of broadly effective prophylactic or therapeutic antiviral strategies (37) . Of these three proteins, UL128 has the lowest variability, with a reported amino acid identity score of 97.0% (37) . In order to evaluate the conservation of the 13B5 binding site within UL128, we aligned 124 UL128 amino acid sequences available in GenBank (data not shown) using Clustal Omega. This alignment included UL128 protein sequences from highly passaged laboratory strains (e.g., AD169 and Towne), common clinical-like strains (e.g., TB40/E and TR), clinical isolates, and HCMV strain Merlin, which is considered the HCMV reference strain. Consistent with previously reported findings, our alignment confirmed that UL128 is highly conserved over almost the entire sequence. We found the highest amino acid 
FIG 3
Binding of human serum antibodies to the UL128 peptide library. An ELISA was performed to determine the reactivity of the UL128 peptide library with commercial serum products from HCMV ϩ (S4360, S4234, and S4371; SeraCare) or HCMV Ϫ (SNeg; SeraCare) individuals or CMV-HIG. Human serum was diluted 1:100, and CMV-HIG was used at a concentration of 1 g/ml.
variability at the UL128 N terminus. In contrast, the UL128 C terminus, ranging from amino acids 148 to 171, which includes the 13B5 binding site, was universally conserved in the analyzed HCMV strains. These data show that the 13B5 binding site is highly conserved in HCMV.
The NAb 13B5 binding site within UL128 is at minimum 13 amino acids long. Linear B cell epitopes vary greatly in length and range from 5 to 22 amino acids (38, 39) , with an average of 15 amino acids (40) . In order to define the amino acid sequence within UL128 that constitutes the 13B5 epitope, we evaluated the binding of 13B5 to N-terminally and C-terminally truncated sequences of peptide 40 of the UL128 peptide library via an ELISA. As mentioned above, peptide 40, composed of the amino acids 157-KRLDVCRAKMGYMLQ-171 of the UL128 protein, demonstrated the strongest binding to the 13B5 antibody and hence was predicted to contain the minimal 13B5 binding sequence (Fig. 2) . The removal of the N-terminal amino acid K and the sequential removal of the four following amino acids (RLDV) from the N terminus of peptide 40 resulted in dramatically reduced 13B5 binding. A complete loss of 13B5 binding was observed by removing six or more N-terminal amino acids from peptide 40 (Fig. 4A) . Truncation of the two C-terminal amino acids LQ from peptide 40 did not show a reduction in 13B5 binding, although slightly decreased 13B5 binding was observed by additionally removing the M residue from the peptide 40 C terminus (Fig. 4B ). 13B5 binding was substantially decreased by the removal of the four C-terminal amino acids YMLQ from peptide 40 and was completely lost when five or more C-terminal amino acids of peptide 40 were removed (Fig. 4B ). These results indicated that a 13-aminoacid-long sequence ranging from K157 to M169 (KRLDVCRAKMGYM) at the C terminus of the UL128 protein is necessary and sufficient for efficient 13B5 binding. In addition, surface plasmon resonance (SPR) analysis showed a comparable and high affinity of the 13B5 antibody for the binding peptides based on the identified minimal 13B5 binding
, supporting that the mapped binding site represents a continuous epitope. To investigate further whether additional amino acid residues localized at the N terminus of K157 of UL128 are critical for 13B5 recognition, we compared 13B5 binding to peptides composed of the defined minimal 13B5 binding site with peptides comprising the 13B5 binding site and one or two additional amino acids (K155 and H156) of UL128 added to the N terminus. As shown in Fig. 4C , the addition of the N-terminal amino acids (KH) to the 13B5 target sequence improved the binding of the 13B5 antibody only minimally, suggesting that these amino acids are not critical for 13B5 binding, but they may slightly improve the interaction of the 13B5 antibody and its target site. As mentioned above, different peptides may bind to plastic with various efficiencies. Thus, minor variations in 13B5 binding of the different peptides may be difficult to interpret, as they may be a result of different efficiencies of peptides for binding to the ELISA plate wells. In sum, these results indicate that NAb 13B5 targets a 13-amino-acid-long continuous epitope sequence at the C terminus of UL128 that is composed of residues 157-KRLDVCRAKMGYM-169 of the protein.
Most residues of the 13B5 target site within UL128 are critical for antibody binding. In order to define the amino acid residues of the 13B5 target site within UL128 that are critical for antibody binding, we serially replaced each residue of the defined 13-amino-acid-long 13B5 binding site with alanine residues and evaluated the influence of these changes on 13B5 binding. Figure 4D of K13M with alanine residues resulted in a dramatically reduced or complete loss of 13B5 binding. In contrast, 13B5 binding was not impaired when one of the internal residues L, D, and V of K13M was replaced. In addition, the substitution of L or D within K13M slightly increased 13B5 binding compared to that of the original K13M sequence, suggesting that these amino acid substitutions slightly improved the interaction of 13B5 and its target sequence. Interestingly, the internal cysteine residue within K13M that appeared essential for 13B5 binding corresponds to amino acid C162 of UL128, which was previously shown to form a disulfide bridge with gL in the PC (35) . This suggests that NAb 13B5 targets a sequence within UL128 that is critical for interactions of the PC subunits. In sum, these results indicate that most of the amino acids of the 13B5 target sequence within UL128 are necessary for 13B5 binding, while three residues within the target site appear not to be critical for 13B5 binding.
Peptides based on the 13B5 target site interfere with HCMV neutralization. For obtaining functional evidence that the identified 13B5 target sequence within UL128 represents a neutralizing epitope, we sought to evaluate whether peptides based on the 13B5 binding site can interfere with 13B5 neutralizing activity. Serial dilutions of the peptides were preincubated with a constant concentration of 13B5 antibody at which the antibody is known to neutralize over 95% of HCMV infection of ARPE-19 EC. The antibody-peptide mixture was then tested via a standard assay on ARPE-19 EC for HCMV neutralization to determine the functional inhibition of the 13B5 antibody. Another potent PC-specific NAb (54E11) that was previously shown to recognize a conformational epitope constituted by UL130/UL131A was used as a control (32) . As shown in Fig. 5 , a strong dose-dependent interference with 13B5-mediated neutralization with over 87% inhibition of 13B5 neutralizing activity at the highest peptide concentration tested was observed only with peptides containing the entire minimal 13B5 target sequence (library peptide 40, K13M, and K14L). A significantly lower inhibition of 13B5 function was observed with library peptide 41 that was missing four were evaluated for interference with 13B5 neutralizing activity to block TB40/E entry into ARPE-19 EC. Peptides were preincubated with 150 ng/ml 13B5 or 50 ng/ml 54E11 as a control and then incubated for 2 h with 9,000 PFU of HCMV TB40/E before the mixture was transferred to the cells.
N-terminal residues of the 13B5 binding site (Table 1) . In contrast, neutralization by 13B5 was not or was only minimally inhibited by peptides in which all (library peptides 37 and 38), most (library peptide 39), or one or two (K12Y and K11G) C-terminal residues of the 13B5 binding site sequence were absent. As expected, none of the tested peptides interfered with the neutralizing function of anti-PC antibody 54E11. These results show that peptides containing the identified 13B5 binding site specifically interfere with the 13B5 neutralizing function, providing functional evidence that the 13B5 target sequence is critically involved in HCMV neutralization.
Peptide construction based on the 13B5 binding site to test antibody induction. To further support whether the identified 13B5 target site represents a neutralizing epitope, we evaluated keyhole limpet hemocyanin (KLH)-coupled peptides based on the 13B5 binding site for immunogenicity to elicit NAb in mice. For this, we generated three different KLH-coupled peptide constructs based on the 13B5 target sequence. In one construct, termed KLH-K15M, KLH was coupled to the minimal 13B5 target sequence (K13M) via the existing internal C162 residue, and two additional residues of UL128 were added to the peptide N terminus, which appeared to slightly increase the binding of the 13B5 antibody (Fig. 4C) . The second construct, named KLH-K14CS, was generated by the coupling of KLH via a C-terminally added C residue to K13M in which the internal C162 residue of the minimal 13B5 target sequence was replaced with a serine. The third construct, termed KLH-K16CS, was generated in a way similar to that used for the second construct (KLH-K14CS), except that it included two additional amino acid residues of UL128 at the N terminus, similarly to the first construct (KLH-K15M). C-to-S amino acid substitutions in the second and third constructs (KLH-K14CS and KLH-K16CS) were chosen because of the similarity in steric occupancy between these two residues. As shown in Fig. 6A , all KLH constructs showed strong binding of the 13B5 antibody, indicating that KLH coupling and amino substitutions did not alter the interaction of the 13B5 target sequence with the 13B5 antibody. As a control, we also generated a peptide construct consisting of library peptide 38 (KLH-38), which only partially overlapped the 13B5 target site (Table 1) . This peptide was similar to a recently tested UL128 peptide that failed to stimulate NAb in rabbits (41) . As expected, KLH-38 was unable to bind the 13B5 antibody (Fig. 6A) . In sum, these results indicated that all KLH-coupled peptide constructs based on the 13B5 epitope sequence presented intact 13B5 binding sites.
Peptides based on the 13B5 target site have the ability to elicit NAb in mice. To test whether the generated KLH-coupled peptide constructs based on the 13B5 target site (KLH-K15M, KLH-K14CS, and KLH-K16CS) have the ability to elicit NAb, BALB/c mice were intraperitoneally immunized three times 4 weeks apart with the peptide constructs admixed in Freund's adjuvant. Levels of serum binding antibodies and NAb were determined 1 week before and 3 weeks after each immunization. Levels of binding antibodies of the individual groups were determined via an ELISA using peptides that were used for immunization as target antigens (Fig. 6C ). The NAb titer at which infection was inhibited by 50% (NT 50 ) was determined by a microneutralization assay using ARPE-19 EC as the cell substrate and HCMV strain TB40/E for infection (Fig.  6D) . As a control, mice were immunized with KLH only or KLH-38 with the C-terminal UL128 peptide sequence that only partially overlapped the 13B5 target site ( Table 1) . As shown in Fig. 6C , all mice immunized with the peptide constructs developed binding antibodies against the peptide sequence with which they were vaccinated after the first immunization. These responses were not or were only minimally boosted by second and third immunizations. In addition, Western blot analysis of UL128 expressed from Ad vectors showed that mice immunized with KLH-K15M, KLH-K14CS, and KLH-K16CS developed antibodies that recognized denatured UL128 (Fig. 6B ). NAb responses with NT 50 values ranging from 200 to 300 were detectable after the first immunization in only two out of five animals in each vaccine group immunized with KLH-K14CS or KLH-K16CS (Fig. 6D) . These responses were boosted in only one animal each in the KLH-K14CS and KLH-K16CS vaccine groups, reaching NT 50 values of 800 to 1,200. These titers remained stable after the third immunization. In the two other animals that developed NAb after the first immunization, NAb levels declined and were undetectable after the booster immunizations. None of the animals immunized with the peptide construct KLH-K15M, the control construct KLH-38, or KLH only developed NAb. These results indicated that peptides based on the 13B5 target site in which the internal cysteine residue was replaced by a serine residue and KLH was coupled via an additional cysteine residue to the C terminus had the ability to elicit NAb in mice. In contrast, peptides composed of the 13B5 target site that were coupled to KLH via the existing internal C162 residue did not show immunogenicity for NAb induction. These results provide evidence that the identified 13B5 target sequence has the potential to elicit NAb, supporting that it constitutes a neutralizing epitope within UL128. Levels of peptide-specific binding antibodies in sera of immunized mice were measured via an ELISA 1 week before (Ϫ1wp1st) and 3 weeks after the first, second, and third immunizations (3wp1st, 3wp2nd, and 3wp3rd, respectively) by using the peptides (not conjugated to KLH) that were used for immunization as coating antigens. (D) Serum neutralizing antibody titers (NT 50 ) from immunized mice against HCMV TB40/E were measured on ARPE-19 EC by using a standard microneutralization assay. Lines in panels C and D indicate the group means.
DISCUSSION
In this study, we provide evidence for the discovery of a linear neutralizing epitope within the HCMV PC, which is thought to be an important target of humoral immune responses preventing congenital HCMV infection. Previous studies demonstrated that the PC comprises predominantly quaternary conformational epitopes that are formed by two or more subunits and in only rare cases epitopes that are constituted by single subunits of the PC (28, 29) . In addition, Ciferri et al. identified amino acid residues that are either in close proximity to or part of conformational neutralizing epitopes within the PC (42) . However, amino acid residues that constitute the minimal target sequence of a potent PC-specific NAb have not been described. By taking advantage of an existing NAb with specificity for UL128 (NAb 13B5) that was previously raised in mice by immunization with the entire PC (32), we defined a continuous NAb target sequence at the C terminus of UL128. This discovery represents the first detailed characterization of a putative neutralizing epitope within the HCMV PC and hence provides a first glimpse into the epitope sequences within the PC that may serve as key targets of protective humoral immunity.
Several observations support that the minimal 13B5 target sequence is located at the C terminus of UL128. Our previous study using intracellular flow cytometry to evaluate 13B5 subunit specificity demonstrated that UL128 is necessary and sufficient for efficient 13B5 binding, indicating that UL128 alone comprises the major amino acid residues that constitute the 13B5 epitope (32) . In addition, the 13B5 target site does not overlap target sites of a panel of PC-specific NAb to conformational epitopes that we isolated previously (32) . Here, we have used Western blot analysis and peptide-based scanning methods to show that a continuous sequence composed of the 13 C-terminal residues 157-KRLDVCRAKMGYM-169 of UL128 is minimally required for 13B5 binding. Without the full complement of these residues, 13B5 binding is dramatically decreased or completely abrogated. Moreover, truncation peptides of UL128 that only partially overlap the 13B5 target site or that correspond to other regions within UL128 are not reactive with the 13B5 antibody, indicating that no other residues within UL128 besides the 13 C-terminal residues contribute to the formation of the 13B5 epitope. This conclusion is further supported by our SPR analysis showing that the 13B5 antibody has a similar and high affinity for binding of peptides based on the 13B5 minimal epitope sequence and purified PC. In addition, our neutralization interference assays and immunization studies provide functional evidence that the identified 13B5 target sequence within UL128 represents a PC-specific neutralizing epitope. Whether additional amino acids or peptide sequences of UL128 or the other PC subunits besides the 13 C-terminal residues of UL128 may minimally contribute to the formation of the 13B5 epitope or the binding of 13B5 to its target sequence within UL128 in the assembled PC can be determined only by detailed structural analysis. Nonetheless, these findings provide the first evidence for the existence of a continuous neutralizing epitope within the UL128 subunit of the HCMV PC.
Considering the strong neutralizing potency of the 13B5 antibody (50% inhibitory concentration [IC 50 ] of 15 ng/ml) (32), which is only slightly lower than those of most other anti-PC NAb (IC 50 of 1 to 10 ng/ml) but exceeds those of most gB-and gH/gL-specific NAb (IC 50 of 100 to 1,000 ng/ml) (28, 29, 32) , the low immunogenicity of the 13B5 peptides for the induction of NAb was unexpected. Whereas all of the 13B5 peptides stimulated robust binding antibodies, only 1 out of 5 mice in each of the vaccine groups immunized with K14CS or K16CS developed long-lasting NAb, and these responses were only modest compared to those observed previously by immunization with the PC. While the reasons for this discrepancy in 13B5 NAb potency and 13B5 peptide immunogenicity for stimulating NAb remain speculative, it is possible that the 13B5 epitope sequence in its native state within the PC forms a helical, bended, or "kinked" three-dimensional structure that is required for NAb induction (43) . Consequently, without structural constraint by PC subunits, the 13B5 epitope structure is only inefficiently or rarely formed. This may account for the inconsistent ability of the KLH-coupled 13B5 peptides to stimulate NAb despite their property of eliciting robust peptide-specific binding antibodies. Therefore, the formation of the three-dimensional 13B5 epitope structure is likely promoted in the presence of the 13B5 antibody; otherwise, we would not expect to observe strong binding of the 13B5 NAb and 13B5-based peptides.
Alternative explanations may account for the low immunogenicity of the 13B5 peptides to stimulate NAb. For example, additional amino acid residues within UL128 or other PC subunits may minimally contribute to the 13B5 epitope structure, rendering the identified 13B5 epitope sequence insufficient for the effective stimulation of NAb (44) . Another possibility is that the 13B5 epitope sequence is simply not optimal for EC-specific NAb induction because the neutralization potency of the 13B5 antibody is lower than those of most other anti-PC NAb. Alternatively, the chosen KLH-coupling strategy, despite the fact that it did not abrogate 13B5 binding, may have interfered with NAb induction by impairing the ability of the epitope sequence to form a properly folded three-dimensional structure. Note that all ELISA binding experiments were performed at a single, near-saturating antibody concentration, which may not have allowed the capture of significant differences in the ELISA absorbance values. This might explain why serum antibodies of mice in all vaccine groups immunized with the 13B5 peptides appear to bind their immunogen peptide efficiently but fail to neutralize the virus in most cases or why KLH-K15M appears to bind the 13B5 antibody with an efficiency similar to those of KLH-K14CS and KLH-K16CS but, unlike KLH-K14CS and KLH-K16CS, is unable to elicit neutralizing responses. Nonetheless, although we observed only limited NAb induction by peptide variants based on the 13B5 epitope, this observation provides further evidence that the identified target sequence represents a PC-specific neutralizing epitope.
Our observations may suggest that the 13B5 target sequence is located within the PC at an antigenic site that is largely protected from immune recognition during natural HCMV infection. The finding that the 13B5 target sequence is universally conserved in a minimum of 124 known HCMV isolates suggests that this invariant sequence plays a critical role in HCMV host cell entry. In line with this, C162 of UL128, which is centrally positioned within the 13B5 target sequence, was previously shown to form a disulfide bond with a cysteine residue in gL (35) , highlighting that the 13B5 binding sequence is located at a critical interaction site of the PC subunits. In addition, the observation that antibodies in HCMV ϩ individuals react only minimally with peptides containing the 13B5 target sequence may suggest that this sequence is only minimally immunogenic or only rarely recognized by the immune system during natural HCMV infection, which is consistent with characteristics of an immunologically "cryptic" epitope (45) . Epitope crypticity is a common pattern of immune evasion and has been described for many other pathogens such as HIV, influenza virus, dengue virus, Plasmodium falciparum, and Bacillus anthracis (45) (46) (47) (48) (49) . While it appears contradictory how the 13B5 epitope can be immunologically cryptic and at the same time a target of potent NAb, this could be explained by differences in the accessibility of the 13B5 binding site during natural HCMV infection. The 13B5 binding site may be largely inaccessible in mature HCMV virions, but it may temporarily unfold, for instance, upon PC receptor binding during HCMV entry (50) . Alternatively, the discrepancy in 13B5 epitope crypticity and 13B5 epitope recognition may be explained by the difference in the definition and meaning of epitope immunogenicity and antibody function. For example, highly conserved neutralizing epitopes of the HIV envelope protein are in many cases poorly immunogenic and induce NAb in only about 1% of the HIV-infected population, but these antibodies are extremely potent in neutralizing HIV (51, 52) . While the details may be different, a parallel to the HIV case can be made in the comparison of the putative low immunogenicity of the 13B5 epitope and the potent ability of the 13B5 antibody to neutralize infection. The 13B5 epitope could be of low immunogenicity because it competes for antibody access with immunodominant nonneutralizing epitopes that are localized in close proximity to the 13B5 NAb binding site (45) . However, only a very small amount of the 13B5 antibody may be required for potent neutralization, which could be associated with either the high affinity of the 13B5 antibody or the small amounts of the PC in HCMV virions (53) .
However, as peptide-based scanning methods apply only for characterizing continuous epitope sequences, which represent only a minority of the epitopes within the HCMV PC, our findings do not allow us to make general conclusions for PC-specific antibodies. Most of the antibodies targeting the PC are specific for more complex epitope structures, and hence, it may well be that many other antibodies bind to an area within the PC that is similar to that of 13B5, although they recognize conformational epitopes rather than continuous sequences. Competition experiments with the 13B5 antibody and antibodies from HCMV ϩ individuals to recognize the PC could clarify whether the 13B5 epitope sequence is located at a common recognition site for PC-specific humoral immune responses. In this context, it may also be possible that the 13B5 epitope within the PC forms a three-dimensional rather than a linear structure and that the 13B5 peptide folds into this structure in the presence of the 13B5 antibody but is not well recognized by lower-affinity serum antibodies of HCMV ϩ individuals. Hence, our conclusion could apply only to continuous epitopes, which occur only very infrequently within the HCMV PC.
In light of the observations made with the 13B5 target sequence, this sequence may have value for a peptide-based vaccine strategy to stimulate or enhance NAb responses in HCMV Ϫ or HCMV ϩ individuals. As naturally acquired immunity as a consequence of primary HCMV infection provides only incomplete protection against reinfection (7), it is hypothesized that vaccine-mediated immunity needs to have improved properties over that stimulated by HCMV itself to alter the outcome of congenital infection. In addition, congenital HCMV infection is more often a result of nonprimary infection (reinfection or reactivation) than of primary infection, suggesting than HCMV ϩ individuals, in addition to HCMV Ϫ individuals, may benefit from a vaccine that is able to augment naturally induced immune responses (7, 54) . How such a vaccine candidate can be realized remains elusive, particularly because of the limited knowledge about the immune correlates of protection. However, based on the universal conservation and the putative crypticity of the 13B5 epitope sequence, it can be surmised that a vaccine strategy based on the 13B5 target sequence would allow the elicitation of broadly effective NAb that are focused on potentially protective antigenic sites without inducing antibodies to less protective or nonprotective epitopes. Such a vaccine approach based either on only the 13B5 epitope or on multiple nonoverlapping linear epitope sequences within the PC could induce antibody responses with improved quality compared to those induced during natural infection and hence provide higher protection efficacy than naturally acquired immunity.
In sum, we provide evidence for the identification of a continuous, 13-amino-acidlong neutralizing epitope at the UL128 C terminus within the HCMV PC that is universally conserved and located at an antigenic site of critical importance for HCMV entry and neutralization. These observations enhance our understating of PC-specific neutralizing epitopes, which represent major targets of NAb responses that are considered essential for protection against congenital HCMV infection. Viruses. HCMV TB40/E expressing green fluorescent protein (GFP) was derived from TB40/Ewt-GFP bacterial artificial chromosome (BAC) DNA, a kind gift from T. A. Shenk and E. A. Murphy (Princeton University, NJ) (55) . HCMV stocks were prepared as previously described (30) . Briefly, ARPE-19 cells were infected with HCMV TB40/E and periodically reseeded until 70 to 80% of the cells expressed GFP. Clarified medium was ultracentrifuged (70,000 ϫ g for 1 h) over 20% (wt/vol) sucrose in Tris-buffered saline (0.1 M Tris-Cl [pH 7.4], 0.1 M NaCl), and concentrated virus was resuspended in Tris-buffered saline and stored at Ϫ80°C until use.
MATERIALS AND METHODS

Cells
Antibodies. Purified 13B5 and 54E11 were obtained from hybridoma cells as previously described (32) . Briefly, hybridoma cells were cultured in Hybridoma-SFM (Thermo). The hybridoma supernatant was collected, and NAb was purified by using a HiTrap Protein G HP column (GE Healthcare, Chicago, IL) according to the manufacturer's instructions. NAb quantification was performed by using BradfordCoomassie brilliant blue dye (Thermo). The Z9G11 unpurified hybridoma supernatant was a kind gift of G. Gerna and E. Percivalle (31) .
Immunoblotting. Immunoblotting to determine 13B5 or mouse serum binding to denatured UL128 was performed by using lysates from cells infected with a UL128-expressing adenoviral vector (kindly provided by David Johnson, Oregon Health & Sciences University, Portland, OR, USA) (56) as previously described (30) . Briefly, ARPE-19 cells were coinfected with 20 multiplicities of infection (MOI) of an adenoviral vector expressing the tetracycline transactivator (Ad tet-trans) alone; UL128 and Ad tet-trans; and UL128, UL130, UL131, gH, gL, and Ad tet-trans. Infected cells were harvested at 4 days postinfection, centrifuged at 300 ϫ g, resuspended in Tris-HCl buffer (10 mM Tris-HCl [pH 7.9], 1.0 mM EDTA, and 1ϫ cOmplete Mini protease inhibitor cocktail tablets [Roche, Basel, Switzerland]), and sonicated. Samples were lysed in loading buffer (2ϫ Laemmli sample buffer, 200 mM dithiothreitol), boiled, and used for SDS-PAGE. Primary antibodies 13B5 and Z9G11 were diluted to 100 ng/ml in phosphate-buffered saline (PBS)-0.1% Tween (PBS-T)-3% bovine serum albumin (BSA). Mouse serum was diluted 1:10,000 in PBS-T-3% BSA. A secondary anti-mouse horseradish peroxidase (HRP) conjugate (Sigma) was employed at a dilution of 1:2,000 in PBS-T-2.5% BSA. Chemiluminescence detection was performed by using the ECL WB substrate (Thermo).
Peptide synthesis. Peptides were synthesized by using the Symphony peptide synthesizer (Protein Technologies, Inc., Tucson, AZ) or by manual synthesis utilizing 9-fluorenylmethoxy carbonyl (Fmoc)-based solid-phase peptide synthesis. Fmoc-protected amino acids, HOBT (N-hydroxybenzotriazole), and HBTU [2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] were purchased from Anaspec (Fremont, CA). DMF (N,N-dimethylformamide) and TFA (trifluoroacetic acid) were purchased from Protein Technologies, Inc. (Tucson, AZ). Preloaded Wang resins were purchased from EMD Millipore (Temecula, CA). Piperidine, DIPEA (N,N-diisopropylethylamine), DICI (N,N=-diisopropylcarbodiimide), EDT (1,2-ethanedithiol), TIS (triisopropylsilane), and NMM (4-methylmorpholine) were purchased from SigmaAldrich (St. Louis, MO). Peptides were purified and characterized by using an Agilent 1200 preparative liquid chromatography/mass spectrometry (LC/MS) system and an Agilent 1260 analytical highperformance liquid chromatography (HPLC) instrument (Agilent Technologies, Santa Clara, CA). A typical synthesis reaction starts with mixing 25 mol of Wang resin with a 20% piperidine-DMF solution to remove the Fmoc-protecting group for 30 min. In the next step, 3 eq of Fmoc-protected amino acid, HBTU, and NMM are added to the resin in a DMF solution. The reaction is mixed under nitrogen for 1 to 2 h. After draining, the resin is washed with DMF, the Fmoc group is removed with 20% piperidine, and the next amino acid in the sequence is added. Once the sequence is complete, the peptide is cleaved from the resin with a cleavage cocktail containing TFA, EDT, water, and TIS overnight. The peptide is collected and precipitated with cold ether. All peptides were purified and characterized individually to at least 80% purity. All peptides were lyophilized to powder and reconstituted in stock solutions for easier development of library pools as well as individual use.
Surface plasmon resonance. Analysis of the affinity of 13B5 for the purified PC and K13M was performed by using a Biacore T100 SPR spectrometer according to the manufacturer's instructions. The Biacore CM5 sensor chip was bound by amine coupling with 13B5. Affinity constants were calculated by using the Biacore T100 software provided by the manufacturer. The HCMV PC was produced and purified as described by Chiuppesi et al. (F. Chiuppesi, F. Wussow, L. Sharf, H. Contreras, H. Gao, Z. Meng, J. Nguyen, P. A. Barry, P. J. Bjorkman, and D. J. Diamond, unpublished data). Briefly, HEK 293-6E cells (NRC-BRI) were cotransfected with plasmids (pTT5; NRC-BRI) encoding HCMV PC subunit genes from TB40/E by using polyethylenimine HCl Max (Polysciences). The supernatant was collected at 10 days posttransfection and purified by using an affinity chromatography column (Hi-Trap NHS-activated HP column; GE Healthcare Bio-Sciences, Pittsburgh, PA) activated with UL128/UL130/UL131A-specific monoclonal antibody 12E2 (32) . Size exclusion chromatography (S200; GE Healthcare Bio-Sciences) was performed on the eluate, and fractions were analyzed by SDS-PAGE followed by Coomassie gel staining.
Keyhole limpet hemocyanin conjugation. Peptides were conjugated to KLH (Thermo) according to the manufacturer's instructions. Briefly, 20 mg of KLH was reacted with 10 mg sulfo-SMCC [sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate] for 1 h at room temperature. After the removal of the excess cross-linker by using a desalting column, 20 mg of the peptide was added, and the mixture was incubated for 2 h at room temperature. To remove the unconjugated peptide, the conjugate was purified by desalting and subsequently aliquoted and stored at Ϫ20°C until use. Conjugate quantification was performed by reading the absorbance at 280 nm and by performing a quantitative ELISA using the peptides as a standard.
Immunizations. Groups of five BALB/c mice (Jackson Laboratory, Bar Harbor, ME) were prime vaccinated with 100 g of a peptide-KLH conjugate (quantified based on the peptide concentration) emulsified with complete Freund's adjuvant (CFA) and boosted two times with 50 g of the peptide-KLH conjugate admixed in incomplete Freund's adjuvant (IFA). Mice were immunized via the intraperitoneal route every 4 weeks. Blood samples were collected by eye bleed 1 week before prime immunization as well as 3 weeks after prime and booster immunizations.
ELISA. For analysis of 13B5 binding to UL128 peptides or to KLH-peptide conjugates, ELISA plates (Thermo) were coated overnight with peptides or KLH-peptide constructs at a dilution of 10 g/ml in PBS. Negative-control wells were coated with PBS alone. After 2 h of blocking with PBS-1% BSA, 13B5 was added at a concentration of 3 g/ml for 2 h. After washing, anti-mouse HRP (Thermo) was added at a dilution of 1:2,000. Plates were developed with the Ultra TMB (3,3=,5,5=-tetramethylbenzidine)-ELISA substrate (Thermo), and the reaction was blocked with 1 M H 2 SO 4 . An ELISA to evaluate the recognition of the UL128 library peptides by human serum was performed by diluting three commercially available sera from HCMV ϩ individuals [lots BM204234 (S4234), BM204360 (S4360), and BM204371 (S4371); SeraCare], HCMV IgG-negative human serum [lot BM216642 (SNeg); SeraCare] at a 1:100 dilution in PBS, and an IgG preparation (CMV-hyperimmune globulin [CMV-HIG]) (Cytogam; Baxter-Healthcare Corp., Irvine, CA) to 1 g/ml. HRP-conjugated goat anti-human IgG secondary antibody (Promega) was diluted 1:2,000 in PBS. Sera from immunized mice were analyzed as described above for human sera but with the differences that the mouse sera were diluted 1:100 in PBS and ELISA plate wells were coated with 10 g/ml of the peptide used to immunize the animals. Sera from mice immunized with only KLH were tested by an ELISA using uncoated wells.
Neutralization assay. ARPE-19 cells were seeded at 1.5 ϫ 10 4 cells/well in a clear-bottom 96-well plate (Corning). Approximately 24 h later, the medium in every plate was replaced with 50 l per well of fresh growth medium. A neutralization assay to analyze serum NAb from immunized mice was performed as previously described (30, 32) . Briefly, serial 2-fold dilutions of the mouse sera were prepared in complete growth medium in a final volume of 75 l. NAb dilutions were mixed with 75 l of complete growth medium containing ϳ9,000 PFU of HCMV TB40/E and incubated for 2 h at 37°C. The mixture was transferred to the cells (50 l each, in duplicate wells). After 48 h, cells were fixed, and IE-1 immunostaining was performed as previously described (30) . The NAb concentration inhibiting 50% of virus infectivity (IC 50 ) was also calculated as previously described (30) . A neutralization assay to quantify peptide-mediated inhibition of antibody neutralizing activity was performed as described above, with a few changes. Serial 2-fold dilutions of the peptides starting from 100 g/ml were incubated with 10 NT 50 s of NAb 13B5 (150 ng/ml) or 54E11 (50 ng/ml) (32) . After 2 h of incubation, ϳ9,000 PFU of HCMV TB40/E were added to each well, and the wells were incubated for an additional 2 h. The mixture was transferred to the cells (50 l each, in duplicate wells), and cells were analyzed after 48 h as described above.
Software. Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) was used to align 124 UL128 amino acid sequences randomly selected from the available complete HCMV genomes in GenBank (http://www.ncbi.nlm.nih.gov/GenBank/).
